Traws Pharma, Inc. (TRAW) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
32/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseTRAW / S&P -54.10% / 15.20% |
LoseTRAW / S&P TRAW unavailable / 15.00% |
LoseTRAW / S&P -39.16% / 50.40% |
| 2026-Q11/3 |
WinTRAW / S&P 61.95% / -4.33% |
LoseTRAW / S&P TRAW unavailable / 11.30% |
LoseTRAW / S&P -92.74% / 27.70% |
| 2025-Q40/3 |
LoseTRAW / S&P -38.92% / 2.65% |
LoseTRAW / S&P TRAW unavailable / 9.00% |
LoseTRAW / S&P -102.97% / 13.40% |
| 2025-Q31/3 |
WinTRAW / S&P 25.00% / 8.12% |
LoseTRAW / S&P TRAW unavailable / 4.61% |
LoseTRAW / S&P -94.80% / 13.45% |
| 2025-Q21/3 |
LoseTRAW / S&P -35.65% / 10.94% |
WinTRAW / S&P 1184.51% / 4.83% |
LoseTRAW / S&P -92.28% / 10.63% |
| 2025-Q11/3 |
LoseTRAW / S&P -74.10% / -4.27% |
LoseTRAW / S&P 0.44% / 4.98% |
WinTRAW / S&P 39.01% / 10.57% |
| 2024-Q42/3 |
WinTRAW / S&P 51.02% / 2.41% |
LoseTRAW / S&P 0.00% / 5.25% |
WinTRAW / S&P 181.80% / 6.15% |
| 2024-Q31/3 |
LoseTRAW / S&P -47.73% / 5.89% |
LoseTRAW / S&P 0.00% / 5.89% |
WinTRAW / S&P 415.83% / 6.11% |
| 2024-Q21/3 |
LoseTRAW / S&P -55.45% / 4.28% |
LoseTRAW / S&P 0.00% / 5.38% |
WinTRAW / S&P 3606.00% / 5.12% |
| 2024-Q12/3 |
WinTRAW / S&P 34.67% / 10.56% |
LoseTRAW / S&P 0.00% / 5.71% |
WinTRAW / S&P 1590.91% / 5.59% |
| 2023-Q41/3 |
LoseTRAW / S&P 5.63% / 11.69% |
LoseTRAW / S&P 0.00% / 6.81% |
WinTRAW / S&P 1119.78% / 7.78% |
| 2023-Q31/3 |
LoseTRAW / S&P -39.83% / -3.27% |
LoseTRAW / S&P 0.00% / 7.52% |
WinTRAW / S&P 687.65% / -5.03% |
| 2023-Q22/3 |
WinTRAW / S&P 61.64% / 8.74% |
LoseTRAW / S&P 0.00% / 9.50% |
WinTRAW / S&P 29.87% / -8.57% |
| 2023-Q12/3 |
WinTRAW / S&P 12.31% / 7.50% |
LoseTRAW / S&P 0.00% / 10.77% |
WinTRAW / S&P 16.47% / -15.69% |
| 2022-Q41/3 |
LoseTRAW / S&P -26.14% / 7.56% |
LoseTRAW / S&P 0.00% / 11.88% |
WinTRAW / S&P -6.19% / -17.99% |
| 2022-Q30/3 |
LoseTRAW / S&P -33.33% / -4.88% |
LoseTRAW / S&P -0.44% / 13.47% |
LoseTRAW / S&P TRAW unavailable / -1.41% |
| 2022-Q20/3 |
LoseTRAW / S&P -28.26% / -16.10% |
LoseTRAW / S&P -4.24% / 13.71% |
LoseTRAW / S&P TRAW unavailable / 11.04% |
| 2022-Q10/3 |
LoseTRAW / S&P -27.84% / -4.60% |
LoseTRAW / S&P -3.83% / 15.97% |
LoseTRAW / S&P TRAW unavailable / 42.23% |
| 2021-Q40/3 |
LoseTRAW / S&P -33.42% / 11.03% |
LoseTRAW / S&P -2.16% / 15.00% |
LoseTRAW / S&P TRAW unavailable / 96.40% |
| 2021-Q31/3 |
LoseTRAW / S&P -44.73% / 0.58% |
WinTRAW / S&P 11.27% / 10.77% |
LoseTRAW / S&P TRAW unavailable / 69.42% |
| 2021-Q21/3 |
LoseTRAW / S&P -53.80% / 8.55% |
WinTRAW / S&P 17.41% / 6.58% |
LoseTRAW / S&P TRAW unavailable / 51.81% |
| 2021-Q11/3 |
WinTRAW / S&P 112.77% / 6.17% |
LoseTRAW / S&P -89.16% / -1.06% |
LoseTRAW / S&P TRAW unavailable / 7.39% |
| 2020-Q41/3 |
WinTRAW / S&P 67.86% / 12.15% |
LoseTRAW / S&P -89.42% / -3.72% |
LoseTRAW / S&P TRAW unavailable / -33.42% |
| 2020-Q30/3 |
LoseTRAW / S&P -50.88% / 8.93% |
LoseTRAW / S&P -90.78% / -2.04% |
LoseTRAW / S&P TRAW unavailable / -27.10% |
| 2020-Q21/3 |
WinTRAW / S&P 90.00% / 20.54% |
LoseTRAW / S&P -91.14% / -0.46% |
LoseTRAW / S&P TRAW unavailable / -27.11% |
| 2020-Q11/3 |
LoseTRAW / S&P -21.05% / -19.60% |
WinTRAW / S&P 196.04% / 3.47% |
LoseTRAW / S&P TRAW unavailable / -14.75% |
| 2019-Q41/3 |
LoseTRAW / S&P -55.29% / 9.07% |
WinTRAW / S&P 77.77% / 5.36% |
LoseTRAW / S&P TRAW unavailable / 2.99% |
| 2019-Q31/3 |
LoseTRAW / S&P -70.18% / 1.70% |
WinTRAW / S&P 68.60% / 5.02% |
LoseTRAW / S&P TRAW unavailable / 0.21% |
| 2019-Q21/3 |
LoseTRAW / S&P -13.64% / 4.30% |
WinTRAW / S&P 74.27% / 6.64% |
LoseTRAW / S&P TRAW unavailable / 8.65% |
| 2019-Q11/3 |
WinTRAW / S&P 56.40% / 13.65% |
LoseTRAW / S&P -35.85% / 8.12% |
LoseTRAW / S&P TRAW unavailable / 14.29% |
| 2018-Q41/3 |
LoseTRAW / S&P -71.25% / -13.52% |
WinTRAW / S&P 56.04% / 9.05% |
LoseTRAW / S&P TRAW unavailable / 18.23% |
| 2018-Q32/3 |
WinTRAW / S&P 22.33% / 7.71% |
WinTRAW / S&P 60.59% / 10.21% |
LoseTRAW / S&P TRAW unavailable / 19.06% |
| 2018-Q20/3 |
LoseTRAW / S&P -52.38% / 3.43% |
LoseTRAW / S&P -44.78% / 9.03% |
LoseTRAW / S&P TRAW unavailable / 14.46% |
| 2018-Q10/3 |
LoseTRAW / S&P -44.00% / -0.76% |
LoseTRAW / S&P -73.35% / 7.68% |
LoseTRAW / S&P TRAW unavailable / 12.46% |
| 2017-Q40/3 |
LoseTRAW / S&P -12.28% / 6.64% |
LoseTRAW / S&P -85.81% / 7.03% |
LoseTRAW / S&P TRAW unavailable / 13.82% |
| 2017-Q30/3 |
LoseTRAW / S&P -20.83% / 4.48% |
LoseTRAW / S&P -94.54% / 5.68% |
LoseTRAW / S&P TRAW unavailable / 17.57% |
| 2017-Q20/3 |
LoseTRAW / S&P -28.95% / 3.09% |
LoseTRAW / S&P -84.22% / 4.83% |
LoseTRAW / S&P TRAW unavailable / 17.74% |
| 2017-Q11/3 |
WinTRAW / S&P 33.92% / 6.07% |
LoseTRAW / S&P -66.59% / 3.67% |
LoseTRAW / S&P TRAW unavailable / 13.32% |
| 2016-Q40/3 |
LoseTRAW / S&P -14.34% / 3.82% |
LoseTRAW / S&P -51.59% / 2.09% |
LoseTRAW / S&P TRAW unavailable / 7.05% |
| 2016-Q31/3 |
LoseTRAW / S&P -54.15% / 3.85% |
WinTRAW / S&P 658.74% / 0.20% |
LoseTRAW / S&P TRAW unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | TRAW total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -57.86% | 20.78% |
| Annualized return | -57.86% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | TRAW total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.55% | 83.14% |
| Annualized return | -66.09% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | TRAW total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 319.30% |
| Annualized return | -64.27% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |